Two triamcinolone acetonide treatments compared for patchy hair loss from alopecia areata
Compares triamcinolone acetonide injections with microneedling plus triamcinolone acetonide in adults with alopecia areata.
Key facts
- Who runs it
- Dow University of Health Sciences
- Where
- Pakistan1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Comparative Effectiveness of Intralesional Injection of Triamcinolone Acetonide vs. Microneedling With Local Application of Triamcinolone Acetonide in the Treatment of Alopecia Areata
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 276 people, planned
- Started
- 1 Jan 2026
- Expected to end
- Dec 2026
- Type of study
- Interventional, 2 groups
- Treatments tested
- Triamcinolone acetonide
- Microneedling with topical triamcinolone acetonide
- Record updated
- 9 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with alopecia areata, a condition that causes patchy hair loss. It compares triamcinolone acetonide injections with microneedling plus triamcinolone acetonide put on the skin.
- Age
- 18 years and older
- Sex
- Men and women
- Disease stage
- Alopecia areata diagnosed by a doctor, covering 25 percent or less of the scalp. The hair loss has lasted up to 12 months.
- Earlier treatment
- No immunosuppressive treatment, by mouth, injection or on the skin, in the last 4 weeks. These are medicines that calm the immune system.
Main reasons for not taking part
- Hair loss on more than 25 percent of the scalp, or total loss of scalp or body hair (alopecia totalis or universalis)
- Scarring hair loss or an active scalp infection
- Past keloids (thick raised scars) or problems with wound healing
- Pregnant or breastfeeding women
- Known allergy to triamcinolone acetonide or local anesthetics
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Male and female participants aged 18 years and above; Clinically diagnosed alopecia areata involving 25 percent or less of the scalp surface area; Disease duration of up to 12 months; Willingness to participate in the study and provide written informed consent
Who cannot take part
- Extensive alopecia areata involving more than 25 percent of the scalp, alopecia totalis, or alopecia universalis; Scarring alopecia or active scalp infection; History of keloid formation or abnormal wound healing; Pregnant or lactating women; Use of systemic or topical immunosuppressive therapy within the last 4 weeks; Known hypersensitivity to triamcinolone acetonide or local anesthetics; Presence of uncontrolled autoimmune disorders that may affect treatment response
This trial is currently available in Pakistan.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Brief Summary
Read full original descriptionShow less
The goal of this clinical trial is to learn which treatment works better for people with alopecia areata, a condition that causes patchy hair loss. The study will compare two commonly used treatments to see which one leads to better hair regrowth and fewer side effects.
The main questions this study aims to answer are:
Does injecting triamcinolone acetonide into the skin lead to better hair regrowth than microneedling with topical triamcinolone acetonide?
Are there any side effects linked to these treatments?
Researchers will compare two groups of participants. One group will receive intralesional injections of triamcinolone acetonide. The other group will receive microneedling followed by the local application of triamcinolone acetonide. The results will be compared to see which treatment works better for alopecia areata.
Participants will:
Be examined by the research team to confirm the diagnosis of alopecia areata
Receive one of the two treatments as part of the study
Attend follow-up visits so researchers can check hair regrowth and monitor for side effects
The 2 groups in the trial
- Intralesional Triamcinolone AcetonideTreatment being tested
Participants in this arm will receive intralesional injections of triamcinolone acetonide into the affected scalp areas at four-week intervals, according to standard clinical practice.
Treatment: Triamcinolone acetonide and Microneedling with topical triamcinolone acetonide
- Microneedling with Topical Triamcinolone AcetonideTreatment being tested
Participants in this arm will undergo microneedling of the affected scalp areas followed by local application of triamcinolone acetonide at four-week intervals.
Treatment: Triamcinolone acetonide and Microneedling with topical triamcinolone acetonide
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Comparative Effectiveness of Intralesional Injection of Triamcinolone Acetonide vs. Microneedling With Local Application of Triamcinolone Acetonide in the Treatment of Alopecia Areata
- Plain-language title
- Two triamcinolone acetonide treatments compared for patchy hair loss from alopecia areataGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 9 November 2026